ATE533858T1 - Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin - Google Patents

Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin

Info

Publication number
ATE533858T1
ATE533858T1 AT06707630T AT06707630T ATE533858T1 AT E533858 T1 ATE533858 T1 AT E533858T1 AT 06707630 T AT06707630 T AT 06707630T AT 06707630 T AT06707630 T AT 06707630T AT E533858 T1 ATE533858 T1 AT E533858T1
Authority
AT
Austria
Prior art keywords
carboplatin
cisplatin
clinical response
chemotherapeutic treatment
predicting clinical
Prior art date
Application number
AT06707630T
Other languages
English (en)
Inventor
Costa Rafael Rosell
Roca Miguel Taran
Original Assignee
Pangaea Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangaea Biotech S L filed Critical Pangaea Biotech S L
Application granted granted Critical
Publication of ATE533858T1 publication Critical patent/ATE533858T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/10Characterised by chemical treatment
    • C12Q2523/125Bisulfite(s)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06707630T 2005-03-16 2006-03-16 Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin ATE533858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075632A EP1702989A1 (de) 2005-03-16 2005-03-16 Verfahren zur Vorhersage der klinischen Reaktion auf die chemotherapeutische Behandlung mit Cisplatin oder Carboplatin
PCT/EP2006/002610 WO2006097346A1 (en) 2005-03-16 2006-03-16 Method of predicting the clinical response to platinum based chemotherapeutic treatment

Publications (1)

Publication Number Publication Date
ATE533858T1 true ATE533858T1 (de) 2011-12-15

Family

ID=34938100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707630T ATE533858T1 (de) 2005-03-16 2006-03-16 Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin

Country Status (9)

Country Link
US (1) US8377888B2 (de)
EP (2) EP1702989A1 (de)
JP (1) JP4954970B2 (de)
AT (1) ATE533858T1 (de)
CA (1) CA2601145A1 (de)
DK (1) DK1863925T3 (de)
ES (1) ES2380117T3 (de)
HK (1) HK1116518A1 (de)
WO (1) WO2006097346A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
DE10161625A1 (de) * 2001-12-14 2003-07-10 Epigenomics Ag Verfahren und Nukleinsäuren für die Analyse einer Lungenzell-Zellteilungsstörung
KR100470221B1 (ko) * 2002-02-20 2005-02-05 굿젠 주식회사 유전자 프로모터 CpG 아일랜드의 메틸화 여부를분석하는 염기서열분석형 올리고뉴클레오타이드칩, 이의제조방법 및 이를 이용한 암 검색방법
JP2007501002A (ja) * 2003-08-01 2007-01-25 ザ ユニバーシティ オブ ウェスタン オーストラリア 癌治療の成功の可能性を予測するための方法及びキット
EP1692255A4 (de) * 2003-11-12 2010-12-08 Univ Boston Isolierung von nukleinsäure aus mundepithelzellen

Also Published As

Publication number Publication date
EP1702989A1 (de) 2006-09-20
EP1863925B1 (de) 2011-11-16
US20090068657A1 (en) 2009-03-12
CA2601145A1 (en) 2006-09-21
JP4954970B2 (ja) 2012-06-20
EP1863925A1 (de) 2007-12-12
WO2006097346A1 (en) 2006-09-21
US8377888B2 (en) 2013-02-19
JP2008532531A (ja) 2008-08-21
ES2380117T3 (es) 2012-05-08
DK1863925T3 (da) 2012-03-12
HK1116518A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
Kim et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing
WO2005098445A3 (en) Lung cancer biomarkers
EP2392678A3 (de) Prognosevorhersage für Kolorektalkrebs
ATE496142T1 (de) Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
Fiskaa et al. Distinct small RNA signatures in extracellular vesicles derived from breast cancer cell lines
BRPI0612169A2 (pt) métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação
ATE548469T1 (de) Verfahren zur identifizierung mehrerer mutationen oder methylierungsmarkern in einem dominierenden hintergrund von wildtyp-dna
ATE531725T1 (de) Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
WO2007087612A8 (en) Detection and diagnosis of smoking related cancers
Shah et al. Occupational exposures and odds of gastric cancer: a StoP project consortium pooled analysis
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
DE602004015626D1 (de) Bei brustkrebs
ATE479095T1 (de) Prozess und reagenzien für extraktion von rns von fraktionierten blutleukozyten
Sureshchandra et al. Chronic heavy drinking drives distinct transcriptional and epigenetic changes in splenic macrophages
Leahy et al. Interleukin-15 is associated with disease severity in viral bronchiolitis
Park et al. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea
ATE533858T1 (de) Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin
Wong et al. Targeting general transcriptional machinery as a therapeutic strategy for adult T-cell leukemia
WO2012054824A3 (en) Prognostic biomarkers in patients with ovarian cancer
Savage et al. The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL)
Chen et al. Genetic polymorphisms of the glycine N-methyltransferase and prostate cancer risk in the health professionals follow-up study
WO2008086800A3 (en) Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
DE112007003223A5 (de) Prognostische Marker für die Klassifizierung des dreijährigen progressionsfreien Überlebens von Patienten mit kolorektalem Karzinom basierend auf Expressionsprofilen von biologischen Proben
Wilson et al. An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias
Khojah et al. Extracellular RNA signatures of mutant KRAS (G12C) lung adenocarcinoma cells